Introduction

Hypertension remains a leading global health concern, with a significant portion of patients failing to achieve target blood pressure (BP) levels on monotherapy. This case study examines the clinical journey of Mr. Robert Johnson, a 58-year-old male with uncontrolled hypertension, and the role of the fixed-dose combination therapy, Zestoretic (lisinopril/hydrochlorothiazide), in managing his condition. Zestoretic combines an angiotensin-converting enzyme (ACE) inhibitor, lisinopril, with a thiazide diuretic, hydrochlorothiazide (HCTZ), offering a synergistic approach to BP reduction.

Patient Presentation and History

Mr. Johnson, a high-school teacher with a sedentary lifestyle, presented for a routine check-up. His medical history was significant for a diagnosis of primary hypertension eight years prior. He reported poor adherence to previous antihypertensive regimens due to multiple daily dosing and side effects, including a persistent dry cough on a previous ACE inhibitor (ramipril) and perceived fatigue on a calcium channel blocker (amlodipine). His social history included a 20-pack-year smoking history (quit 5 years ago) and occasional alcohol consumption. Family history was positive for cardiovascular disease.

At presentation, his BP was 162/98 mmHg in both arms, confirmed on two separate visits. Physical examination was unremarkable except for mild obesity (BMI 31 kg/m²). Initial laboratory tests revealed normal renal function (eGFR 78 mL/min/1.73m²), serum potassium of 4.2 mmol/L, and fasting blood glucose at the upper limit of normal. A diagnosis of uncontrolled stage 2 hypertension was confirmed.

Treatment Strategy and Rationale for Zestoretic

The therapeutic goals were to reduce BP to <130/80 mmHg, improve adherence, and mitigate cardiovascular risk. Given his previous challenges, a simplified, effective, and well-tolerated regimen was paramount. The choice of Zestoretic 20/12.5 mg (containing 20 mg lisinopril and 12.5 mg HCTZ) was based on several factors:

1. 
   
2. Synergistic Mechanism: Lisinopril reduces BP by inhibiting the renin-angiotensin-aldosterone system (RAAS), causing vasodilation. HCTZ promotes sodium and water excretion, reducing plasma volume. The diuretic-induced volume depletion also stimulates the RAAS, which is concurrently blocked by the ACE inhibitor, leading to enhanced efficacy.
   
3. Adherence: A single-tablet, once-daily combination directly addressed his history of non-adherence to multi-pill regimens.
   
4. Metabolic Profile: While HCTZ can cause hypokalemia and slight glucose elevation, the concurrent use of lisinopril helps counteract potassium loss. His baseline labs supported this choice.
   
5. Cardiorenal Protection: ACE inhibitors offer proven benefits in reducing cardiovascular events and slowing renal disease progression, which was advantageous given his risk profile.
   

Clinical Course and Monitoring

Mr. Johnson was started on Zestoretic 20/12.5 mg once daily in the morning. He was counseled on lifestyle modifications, including dietary sodium restriction, increased physical activity, and weight management. A follow-up appointment was scheduled for four weeks.

At the four-week follow-up, Mr. Johnson reported no significant side effects, notably no recurrence of the dry cough. He expressed high satisfaction with the single-pill regimen. His home BP logs showed a progressive decline. Office BP measured 148/92 mmHg—an improvement but still above target. His serum potassium was 3.9 mmol/L, and renal function remained stable.

Given the partial response, the dose was uptitrated to Zestoretic 20/25 mg (20 mg lisinopril/25 mg HCTZ). After another six weeks on the higher dose, his office BP was 128/82 mmHg. Home readings consistently averaged 125-130/78-82 mmHg. He reported mild, transient lightheadedness during the first week of dose escalation, which resolved. Repeat labs showed serum potassium at 3.8 mmol/L (low-normal), creatinine within normal limits, and a slight increase in fasting glucose to the pre-diabetic range, which was noted for continued monitoring.

After six months of sustained control on Zestoretic 20/25 mg, Mr. Johnson's BP averaged 126/80 mmHg. He reported excellent adherence. Annual laboratory monitoring showed stable electrolytes and renal function, with his fasting glucose managed through continued lifestyle efforts.

Discussion and Outcomes

Mr. Johnson's case illustrates several key points in modern hypertension management. First, it underscores the high prevalence of uncontrolled hypertension and the common barrier of medication adherence. The switch to a fixed-dose combination like Zestoretic directly improved adherence by simplifying his regimen, a critical factor in his success.

Second, the case demonstrates the efficacy of rational combination therapy. The complementary mechanisms of lisinopril and HCTZ provided additive antihypertensive effects, allowing for BP control that was unattainable with his previous sequential monotherapies. The need for dose escalation also highlights that achieving stringent BP targets often requires adequate dosing of combination therapy.

Third, https://corazondecarcar.es/) the importance of monitoring was evident. While Zestoretic was generally well-tolerated, vigilance for metabolic changes—particularly potassium and glucose levels—was essential. The ACE inhibitor component helped mitigate diuretic-induced hypokalemia, but levels required monitoring. The slight glucose elevation necessitated reinforced lifestyle counseling but did not, in this case, require discontinuation of therapy given the significant cardiovascular benefit of achieving BP control.

The successful outcome for Mr. Johnson included not only achieving and maintaining his BP goal but also reducing his calculated 10-year cardiovascular risk. The therapy's tolerability profile was crucial for long-term persistence.

Conclusion

This case study of Mr. Johnson highlights Zestoretic as an effective therapeutic option for patients with uncontrolled hypertension, particularly where adherence and synergistic BP lowering are primary concerns. By combining lisinopril and hydrochlorothiazide in a single tablet, it addressed the multifactorial pathophysiology of hypertension, simplified the treatment regimen, and provided a favorable balance of efficacy and tolerability. His journey emphasizes that for many patients with stage 2 hypertension, initiating or switching to a fixed-dose combination may be a more effective strategy than monotherapy, leading to faster and more sustained BP control and improved long-term cardiovascular outcomes. As always, treatment must be individualized, with appropriate patient education and ongoing monitoring for efficacy and safety.